Angiotensin II

Bellomo R[1-5], Zarbock A[6], Landoni G[7,8]

1. Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University; Melbourne, Australia.

2. Department of Critical Care, University of Melbourne, Melbourne, Australia

3. Data Analytics Research and Evaluation Centre, Austin Hospital, Australia

4. Department of Intensive Care, Austin Hospital; Melbourne, Australia.

5. Department of Intensive Care, Royal Melbourne Hospital, Melbourne, Australia

6. Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany

7. Vita-Salute San Raffaele University, Milan, Italy

8. IRCCS San Raffaele Scientific Institute, Milan, Italy

Corresponding author:

Rinaldo Bellomo MD PhD

Department of Intensive Care

Austin Hospital, Heidelberg, Melbourne, Victoria 3084, Australia

e-mail: Rinaldo.bellomo@austin.org.au

Tel: +61-3-9496 5992

Fax: +61-3-9496 3932

Supplemental Table 1: Prospective comparative studies of angiotensin II therapy

First author & Journal	Design	Population	Patients	Comparator	Outcomes
Chawla L (Crit Care 2014; 18:534)	DB RCT	Vasodilatory shock	20	NOREPI	Decreased NOREPI dose with ANGII
Khanna A (N Engl J Med 2017; 377:419-430)	DB RCT	Refractory vasodilatory shock	344	NOREPI/AVP	Decreased NOREPI dose and increased MAP with ANGII.
Coulson T (Anaesthesia 2022;77: 999-1009)	DB RCT	Cardiac surgery	60	NOREPI	Equivalent hemodynamic effects, decreased duration of ICU stay with ANGII.
See EJ (Shock2023;59:691-696)	Before & after trial	Vasodilatory hypotension	120	NOREPI/AVP	Similar hemodynamic effects. With ANGII: decreased ICU mortality; decreased troponin levels and decreased peak creatinine in patients exposed to RAAS inhibitors before treatment.

DB: double blind; RCT: randomized controlled; NOREPI: norepinephrine; AVP: arginine vasopressin; ANGII: angiotensin II; RAAS: Renin angiotensin aldosterone system